Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kohei Kaku, Rina Chin, Yusuke Naito, Hristo Iliev, Rie Ikeda, Kaori Ochiai & Atsutaka Yasui. (2020) Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study. Expert Opinion on Drug Safety 19:2, pages 211-221.
Read now
Read now
André J. Scheen. (2018) The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 17:8, pages 837-848.
Read now
Read now
Articles from other publishers (23)
Mohammad Saifuddin, Ajit Kumar Paul, Sultana Marufa Shefin, Md. Jahangir Alam, Shahjada Selim, Sunjida Islam, Tanjina Hossain, Sadiqa Tuqan, Nusrat Sultana, Marufa Mustari, Ramen Chandra Basak, Kazi Ali Aftab, Indrajit Prasad, Mohammad Rafiq Uddin, Shoma Sharker, Md. Abu Jar Gaffar, Mohammad Motiur Rahman, Mohammad Abdul Hannan, Afsar Ahammed & A.B.M. Kamrul-Hasan. (2024) Evaluation of Efficacy and Safety of Empagliflozin in Bangladeshi Patients with Type 2 Diabetes Mellitus (EFFISAEM Study). Indian Journal of Endocrinology and Metabolism.
Crossref
Crossref
Jiao Chen, Chunxia Jiang, Man Guo, Yan Zeng, Zongzhe Jiang, Dongmin Zhang, Mengqin Tu, Xiaozhen Tan, Pijun Yan, XunMei Xu, Yang Long & Yong Xu. (2024) Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovascular Diabetology 23:1.
Crossref
Crossref
Mustafa Tanrıverdi, Mehmet Baştemir, Hadiye Demirbakan, Alperen Ünalan, Merve Türkmen & Gülşen Özkan Tanrıverdi. (2023) Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocrine Disorders 23:1.
Crossref
Crossref
Eric Pasqualotto, Janine Midori Figueiredo Watanabe, Douglas Mesadri Gewehr, Raphaela da Silva Maintinguer, Simone van de Sande‐Lee, Gustavo Neves de Araujo, Fidel Silveira Leal & Carlos Eduardo Andrade Pinheiro. (2023) Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 25:7, pages 1794-1802.
Crossref
Crossref
Deep Dutta, Jyoti Kadian, Kunal Mahajan, Anil Dhall & Meha Sharma. (2023) Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 17:3, pages 102742.
Crossref
Crossref
Azizul Hasan Aamir, Umar Yousaf Raja, Faisal Masood Qureshi, Ali Asghar, Saeed Ahmed Mahar, Ibrar Ahmed, Tahir Ghaffar, Jamal Zafar, Mohammad Imtiaz Hasan, Amna Riaz, Syed Abbas Raza, Irshad Ahmed Khosa, Jahanzeb Khan & Jaffer Bin Baqar. (2022) Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial. BMC Endocrine Disorders 22:1.
Crossref
Crossref
Max Egers & Marijane Hynes. (2022) Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. Journal of Kidney Care 7:5, pages 216-224.
Crossref
Crossref
Ting Cao, Rui Ni, Weimin Ding, Xiaoyun Ji, Lan Li, Guangneng Liao, Yanrong Lu, Guo-Chang Fan, Zhuxu Zhang & Tianqing Peng. (2022) MLKL-mediated necroptosis is a target for cardiac protection in mouse models of type-1 diabetes. Cardiovascular Diabetology 21:1.
Crossref
Crossref
Fahad M. Althobaiti, Safaa M. Alsanosi, Alaa H. Falemban, Abdullah R. Alzahrani, Salma A. Fataha, Sara O. Salih, Ali M. Alrumaih, Khalid N. Alotaibi, Hazim M. Althobaiti, Saeed S. Al-Ghamdi & Nahla Ayoub. (2022) Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study. Journal of Clinical Medicine 11:16, pages 4769.
Crossref
Crossref
Ryan Pelletier, Kelvin Ng, Wajd Alkabbani, Youssef Labib, Nicolas Mourad & John-Michael Gamble. (2021) Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Therapeutic Advances in Drug Safety 12, pages 204209862198913.
Crossref
Crossref
Fan Yang, Ran Meng & Da‐Long Zhu. (2020) Cardiovascular effects and mechanisms of sodium‐glucose cotransporter‐2 inhibitors. Chronic Diseases and Translational Medicine 6:4, pages 239-245.
Crossref
Crossref
Ajitesh Roy, Animesh Maiti, Anirban Sinha, Arjun Baidya, Asish Kumar Basu, Dasarathi Sarkar, Debmalya Sanyal, Dibakar Biswas, Indira Maisnam, Kaushik Pandit, Moutusi Raychaudhuri, Nilanjan Sengupta, Partha Pratim Chakraborty, Pradip Mukhopadhyay, Pradip Raychaudhuri, Pranab Kumar Sahana, Purushottam Chatterjee, Rana Bhattacharjee, Ranen Dasgupta, Ravi Kant Saraogi, Salil Kumar Pal, Sarmishtha Mukhopadhyay, Satinath Mukhopadhyay, Soumik Goswami, Subhankar Chowdhury & Sujoy Ghosh. (2020) Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement. Diabetes Therapy 11:12, pages 2791-2827.
Crossref
Crossref
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang & Jun Liang. (2019) Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. Medicine 98:49, pages e18245.
Crossref
Crossref
Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad & M. Shahar Yar. (2019) Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. European Journal of Medicinal Chemistry 184, pages 111773.
Crossref
Crossref
Janet B. McGill & Savitha Subramanian. (2019) Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. The American Journal of Cardiology 124, pages S45-S52.
Crossref
Crossref
Janet B. McGill & Savitha Subramanian. (2019) Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. The American Journal of Medicine 132:10, pages S49-S57.e5.
Crossref
Crossref
Ahmed A.M Abdel-Hamid & Alaa El-Din L. Firgany. (2019) Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes. Annals of Anatomy - Anatomischer Anzeiger 224, pages 153-160.
Crossref
Crossref
Awadhesh Kumar Singh, Ambika G. Unnikrishnan, Abdul H. Zargar, Ajay Kumar, Ashok K. Das, Banshi Saboo, Binayak Sinha, Kalyan Kumar Gangopadhyay, Pradeep G. Talwalkar, Samit Ghosal, Sanjay Kalra, Shashank Joshi, Surendra Kumar Sharma, Usha Sriram & Viswanathan Mohan. (2019) Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Therapy 10:2, pages 393-428.
Crossref
Crossref
Manash P Baruah & Sanjay Kalra. (2019) Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study. European Endocrinology 15:2, pages 113.
Crossref
Crossref
Yun-Jing Zhang, Shi-Liang Han, Xi-Feng Sun, Shu-Xiang Wang, Hong-Yun Wang, Xiao Liu, Li Chen & Ling Xia. (2018) Efficacy and safety of empagliflozin for type 2 diabetes mellitus. Medicine 97:43, pages e12843.
Crossref
Crossref
Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Uwe Hehnke, Jyothis T. George, Odd Erik Johansen & David Fitchett. (2018) Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®. Diabetologia 61:7, pages 1522-1527.
Crossref
Crossref
Pattanaik S.R. (2018) EFFICACY AND SAFETY OF ADDITION OF EMPAGLIFLOZIN IN DIABETIC PATIENTS UNCONTROLLED WITH GLIMEPIRIDE + METFORMIN + TENELIGLIPTIN. Journal of Evidence Based Medicine and Healthcare 4:14, pages 1226-1230.
Crossref
Crossref
E Lioudaki, M Whyte, ES Androulakis, KG Stylianou, EK Daphnis & ES Ganotakis. (2017) Renal Effects of SGLT‐2 Inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks. Clinical Pharmacology & Therapeutics 102:3, pages 470-480.
Crossref
Crossref